How, if at all, have you changed your approach to the use of escitalopram for agitation in Alzheimer's dementia based on results from the S-CitAD RCT?

I have changed my approach to the use of escitalopram for agitation in AD only slightly based on this article. For treatment of agitation in AD, the first line is always going to be non-pharmacologic, based on the acknowledge, reassure, and redirect strategy. Caregivers need to be taught to respond,...

The S-CitAD trial results have changed preference from escitalopram over citalopram to citalopram over escitalopram. Citalopram is R-enatiomer and escitalopram is the S-enantiomer. This study was underpowered due to difficulty in recruitment and randomized only 173 patients rather than the intended ...